Digital label management
    1.
    发明授权

    公开(公告)号:US11615160B2

    公开(公告)日:2023-03-28

    申请号:US17242770

    申请日:2021-04-28

    Applicant: IQVIA Inc.

    Abstract: Embodiments of the present disclosure provide a method for monitoring/tracking the lifecycle of a drug from build (e.g., as part of clinical trial development), to approval (e.g., regulatory), to in-market (e.g., distribution and safety information). The use of artificial intelligence (AI) and blockchain technology may enable the system to track the drug down to the prescription level and may support a digital label that can be updated as necessary based on such monitoring (e.g., that can be amended based on safety information detected while the drug is in market and warnings sent out upon amendment).

    DIGITAL LABEL MANAGEMENT
    2.
    发明公开

    公开(公告)号:US20230281261A1

    公开(公告)日:2023-09-07

    申请号:US18189393

    申请日:2023-03-24

    Applicant: IQVIA Inc.

    CPC classification number: G06F16/9554 G16H20/00 G06K7/1417 G06K19/06009

    Abstract: Embodiments of the present disclosure provide a method for monitoring/tracking the lifecycle of a drug from build (e.g., as part of clinical trial development), to approval (e.g., regulatory), to in-market (e.g., distribution and safety information). The use of artificial intelligence (AI) and blockchain technology may enable the system to track the drug down to the prescription level and may support a digital label that can be updated as necessary based on such monitoring (e.g., that can be amended based on safety information detected while the drug is in market and warnings sent out upon amendment).

    DIGITAL LABEL MANAGEMENT
    3.
    发明申请

    公开(公告)号:US20220350854A1

    公开(公告)日:2022-11-03

    申请号:US17242770

    申请日:2021-04-28

    Applicant: IQVIA, INC.

    Abstract: Embodiments of the present disclosure provide a method for monitoring/tracking the lifecycle of a drug from build (e.g., as part of clinical trial development), to approval (e.g., regulatory), to in-market (e.g., distribution and safety information). The use of artificial intelligence (AI) and blockchain technology may enable the system to track the drug down to the prescription level and may support a digital label that can be updated as necessary based on such monitoring (e.g., that can be amended based on safety information detected while the drug is in market and warnings sent out upon amendment).

    Digital label management
    4.
    发明授权

    公开(公告)号:US12271435B2

    公开(公告)日:2025-04-08

    申请号:US18189393

    申请日:2023-03-24

    Applicant: IQVIA Inc.

    Abstract: Embodiments of the present disclosure provide a method for monitoring/tracking the lifecycle of a drug from build (e.g., as part of clinical trial development), to approval (e.g., regulatory), to in-market (e.g., distribution and safety information). The use of artificial intelligence (AI) and blockchain technology may enable the system to track the drug down to the prescription level and may support a digital label that can be updated as necessary based on such monitoring (e.g., that can be amended based on safety information detected while the drug is in market and warnings sent out upon amendment).

Patent Agency Ranking